Cansino Biologics, Inc. Class ASSE: 688185

Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia

· Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis